Switching to IV golimumab from IV infliximab improves disease activity in RA
USA: Switching to IV-golimumab from IV-infliximab is beneficial in patients with rheumatoid arthritis (RA) as it may improve drug tolerance and disease activity, reveals a recent study involving real-world patients.
"Results of the study using RISE data indicate the effectiveness of IV-golimumab in improving RA disease activity in a patient population switching directly from IV-infliximab," John Tesser, Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, USA, and colleagues wrote in their study published in the journal Clinical Rheumatology. This was measured by a standard disease activity index aligned with ACR and EULAR treat-to-target guidelines called CDAI.
"These results are clinically meaningful and may be helpful in providing patients with improved and sustained outcomes given the limited real-world data reporting the efficacy of IV-infliximab-to-IV-golimumab switching."
Golimumab and infliximab are intravenously (IV) administered tumor necrosis factor inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis with concomitant methotrexate. However, due to the differences in their biological construct, patients with rheumatoid arthritis (RA) with a failure response to IV-infliximab may benefit from switching to IV-golimumab.
Using real-world data from ACR's Rheumatology Informatics System for Effectiveness (RISE), Dr. Tesser and colleagues aimed to evaluate the efficacy of switching from IV-infliximab to IV-golimumab to control RA disease activity. RISE is a large electronic health records registry based in the USA.
The longitudinal, retrospective, single-arm study included adults with ≥ 1 RA diagnosis code between 2014 and 2018 and ≥ 1 IV-infliximab prescription within 6 months of a new IV-golimumab order (index date). Clinical Disease Activity Index (CDAI) was used to calculate longitudinal assessments of disease activity in patients continuing IV-golimumab for 6–9- and 9–12-months post-switch. During the follow-up periods, paired t-tests evaluated significance of mean improvements.
The study revealed the following findings:
- Most RA patients with disease activity assessments during the 6-month follow-up (N = 100; mean age: 65.3 years; 81% female; 74% white) demonstrated moderate-to-high disease activity (CDAI: 73% [38/52]) at enrollment.
- On average, patients showed significant improvement in disease activity within 6–9 months of switching; mean CDAI scores improved from 21.3 to 14.1 and were durable through 9–12 months of treatment.
- Real-world patients with moderate-to-high disease activity who switched from IV-infliximab to IV-golimumab demonstrated significant and sustained improvements post-switch as measured by the CDAI.
"Given the limited real-world data documenting efficacy of IV-infliximab-to-IV-golimumab switching, these results are clinically meaningful and may assist clinicians in providing patients with improved and sustained outcomes," the authors concluded.
Reference:
Tesser, J., Lin, I., Shiff, N.J. et al. Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry. Clin Rheumatol (2022). https://doi.org/10.1007/s10067-022-06116-z
KEYWORDS: rheumatoid arthritis, golimumab, infliximab, IV, intravenous, Clinical Rheumatology, disease activity, tumor necrosis factor, John Tesser, drug tolerance
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.